FABHALTA: A first-of-its-kind targeted C3G treatment

FABHALTA^® is the first and only FDA-approved oral complement 3 glomerulopathy (C3G) treatment that targets the complement system. FABHALTA is a treatment for adults with C3G to reduce proteinuria.

In C3G, the complement system (a part of your immune system that helps fight infections) becomes overactive, resulting in a buildup of C3 in your kidneys as well as inflammation.